1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

18 Sep 2019
Admin
News Article

Glenmark Receives Orphan Drug Designation For Its Antibody Candidate For Multiple Myeloma

Drug Firm Glenmark Pharmaceuticals On Tuesday Said It Has Received Orphan Drug Designation For Its Antibody Candidate Gbr 1342 Which Is Under Development For The Treatment Of Patients With Multiple Myeloma Who Have Received Prior Therapies. The United States Food And Drug Administration (Usfda) Has Granted Orphan Drug Designation (Odd) To Company'S Bispecific Antibody Candidate Gbr 1342 That Is Being Investigated For The Treatment Of Multiple Myeloma, Glenmark Said In A Statement.The Candidate Is One Of Five Clinical-Stage Assets In The Pipeline Of Glenmark'S New Innovation Company, It Added."As One Of Our First Important Pipeline Milestones, We Are Excited That The Fda Has Recognised The Potential For Gbr 1342 To Offer A Significant Advancement For Patients With Multiple Myeloma," Alessandro Riva, Md And Ceo Of The New Company (Which Is Yet To Be Named) Said.The Usfda Grants Orphan Drug Designation To Novel Drugs And Biologics That Are Intended For The Safe And Effective Treatment, Diagnosis Or Prevention Of Rare Diseases Or Disorders That Affect Fewer Than 2 Lakh People In The Us, Glenmark Said.The Designation Allows Manufacturers To Qualify For Various Incentives, Including Tax Credits For Qualified Clinical Trials And, Upon Regulatory Approval, Seven Years Of Market Exclusivity, It Added.Shares Of Glenmark Pharmaceuticals Were Trading At Rs 374.60 Per Scrip On Bse, Up 0.28 Per Cent From Its Previous Close.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!